CFB
BMY.RT

Cullen/Frost Bankers’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Cullen/Frost Bankers’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,939
Closed -$1K – 1169
2020
Q4 		$1K Sell
1,939
-75
-4% -$160 ﹤0.01% 1056
2020
Q3 		$5K Sell
2,014
-44
-2% -$126 ﹤0.01% 973
2020
Q2 		$7K Buy
2,058
+1,294
+169% +$4.67K ﹤0.01% 943
2020
Q1 		$3K Sell
764
-17,838
-96% -$58.8K ﹤0.01% 846
2019
Q4 		$56K Buy
+18,602
New +$48.4K ﹤0.01% 583

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Cullen/Frost Bankers's BMY.RT Position: Q1 2021 in Review

Cullen/Frost Bankers sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,939 shares — an estimated $1K sold.

Cullen/Frost Bankers first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $56K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Cullen/Frost Bankers reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Cullen/Frost Bankers sold 1,939 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Cullen/Frost Bankers first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Cullen/Frost Bankers's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $56K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Cullen/Frost Bankers's 13F filing for Q1 2021, filed 5 May 2021.